Date | Title | Description | |
---|---|---|---|
21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
22 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 March and 21 March 2024 | Download |
15 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 March and 14 March 2024 | Download |
12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |
08 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 March and 7 March 2024 | Download |
07 Mar 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |